To further validate the relationship between SPRY4-IT1 and SKA2 on biological activity in breast cancer cells, we examined SKA2 levels (Figure 6A,B) and screened the most effective siRNAs of SKA2 after transfection with SKA2-specific siRNA or a non-targetting control siRNA for 24 h (Figure 6C,D). The gene discussed is SKA2; the disease is breast cancer.